Skip to contentR
Roivant Sciences Ltd.
R
ROIVRoivant Sciences Ltd. Q2 2024 · 10-Q
Revenue$4.48M$4.48M+22.7% vs Q2 2023 Net Income-$230.18M-$230.18MN/M vs Q2 2023 EPS Diluted-$0.31-$0.31N/M vs Q2 2023 Operating Income-$341,713,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Roivant Sciences Ltd. · CIK 1635088 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$267,802,000N/M Margins · derivedOperating margin-7636.0%−1772.8 pt vs Q2 2023
Net margin-5143.8%+3198.5 pt vs Q2 2023
ended Sep 30, 2024 · filed Nov 12, 2024 · 43 d after period end